[Federal Register Volume 78, Number 126 (Monday, July 1, 2013)]
[Notices]
[Pages 39340-39341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-15563]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Patheon Pharmaceuticals, Inc.

    By Notice dated March 20, 2013, and published in the Federal 
Register on March 28, 2013, 78 FR 19016, Patheon

[[Page 39341]]

Pharmaceutical, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric 
Acid (2010), a basic class of controlled substance listed in schedule 
I.
    The company plans to manufacture the listed controlled substance 
for clinical trials and distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Patheon Pharmaceuticals, Inc., to manufacture the listed basic class of 
controlled substance is consistent with the public interest at this 
time. DEA has investigated Patheon Pharmaceuticals, Inc., to ensure 
that the company's registration is consistent with the public interest. 
The investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

    Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-15563 Filed 6-28-13; 8:45 am]
BILLING CODE 4410-09-P?>